News about Global Pharma

AbbVie Seeks EMA Approval for Subcutaneous SKYRIZI in Crohn's Disease

AbbVie submits an European Medicines Agency (EMA) application for subcutaneous SKYRIZI induction in adults with moderately to severely active Crohn’s Disease (CD), supported by phase 3 AFFIRM data.

Global Pharma | 27/08/2026 | By News Bureau

Fosun Pharma Announces 2026 Interim Results

Fosun Pharma announces its 2026 interim results, highlighting accelerating globalisation and value realisation from its innovative drug portfolio.

Global Pharma | 27/08/2026 | By News Bureau

Piramal Alternatives Invests INR 215 Crore in Kolors Healthcare to Drive Wellness Business Expansion

Piramal Alternatives has invested INR 215 crore in Kolors Healthcare to accelerate clinic expansion, strengthen infrastructure and support the wellness company’s Kolors 2.0 transformation.

Global Pharma | 26/08/2026 | By News Bureau

AlzeCure Receives USD 10 Million Upfront Payment from Eli Lilly for Alzheimer's Drug Programme

AlzeCure Pharma has received a USD 10 million upfront payment from Eli Lilly, completing the initial transaction for global rights to its Alzstatin Alzheimer's programme and ACD680.

Global Pharma | 20/08/2026 | By News Bureau

Chugai Files for Expanded Tecentriq Use in MSI-High Colon Cancer in Japan

Chugai Pharmaceutical has filed a Japanese regulatory application seeking an expanded Tecentriq indication for adjuvant treatment of MSI-High colon cancer. The filing is backed by Phase 3 ATOMIC data showing three-year disease-free survival of 86.3 percent with Tecentriq plus mFOLFOX6, versus 76.2 percent with chemotherapy alone.

Global Pharma | 17/08/2026 | By News Bureau

Aurobindo Pharma Unit Receives US FDA Warning Letter; No Impact on US Supplies

Aurobindo Pharma’s Eugia Pharma Specialities has received a US FDA warning letter for its Telangana facility, while the company said existing US supplies remain unaffected.

Global Pharma | 14/08/2026 | By News Bureau |  166

Cycle Pharma Selects Forma Life Sciences for US Supply of FDA-Approved CAVHANZA

Cycle Pharmaceuticals selects Forma Life Sciences to establish US commercial supply of Food and Drug Administration (FDA)-approved CAVHANZA (nilotinib) for Philadelphia chromosome-positive CML patients.

Global Pharma | 13/08/2026 | By News Bureau |  112

Pharming Launches Joenja in Japan for APDS Patients Aged 4 Years and Older

Pharming has launched Joenja (leniolisib) in Japan for adults and children aged 4 years and older with APDS, marking its first commercial availability for children aged 4 to 11 years.

Global Pharma | 13/08/2026 | By News Bureau

Fresenius Kabi Recalls Tyenne Injection Vials Over Glass Particles

Fresenius Kabi recalls one lot of Tyenne (tocilizumab-aazg) 400 mg/20 mL injection vials nationwide after glass particles were found in the product.

Global Pharma | 12/08/2026 | By News Bureau

Innovent and Daiichi Sankyo Partner for Vanflyta Commercialisation in China

Innovent Biologics and Daiichi Sankyo have entered an exclusive agreement to commercialise Vanflyta in China, expanding access for FLT3-ITD positive AML patients.

Global Pharma | 11/08/2026 | By News Bureau